Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide + low-dose dexamethasone followed by rituximab, autologous transplant, and lenalidomide maintenance in newly diagnosed Waldenström macroglobulinemia
2010-020868-38Phase 2Terminated
- Sponsor
- ASL Roma 2
- Start
- Dec 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide, dexamethasone and rituximab in Waldenström macroglobulinemia (WM), sponsored by ASL Roma 2. Primary endpoint: Progression-free survival at 3 years. Started Dec 2010; status: terminated.
02
Drugs
lenalidomidedexamethasonerituximab
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on 2010-020868-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020868-38.